Revelation Biosciences, Inc.
REVB
$1.01
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 52.54% | 38.78% | 39.97% | 5.64% | 1.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.80% | 47.61% | 46.62% | 8.14% | -2.43% |
| Operating Income | -48.80% | -47.61% | -46.62% | -8.14% | 2.43% |
| Income Before Tax | -35.96% | -46.71% | -45.51% | 14.92% | 70.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.96% | -46.71% | -45.51% | 14.92% | 70.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.96% | -46.71% | -45.51% | 14.92% | 70.86% |
| EBIT | -48.80% | -47.61% | -46.62% | -8.14% | 2.43% |
| EBITDA | -48.90% | -47.78% | -46.89% | -8.20% | 2.43% |
| EPS Basic | 96.90% | 89.31% | 97.24% | 95.60% | -- |
| Normalized Basic EPS | 92.88% | 96.30% | 97.24% | 98.20% | -- |
| EPS Diluted | 96.90% | 89.31% | 97.24% | 95.60% | -- |
| Normalized Diluted EPS | 92.88% | 96.30% | 97.24% | 98.20% | -- |
| Average Basic Shares Outstanding | 1,808.02% | 3,865.02% | 5,173.36% | 4,622.86% | -- |
| Average Diluted Shares Outstanding | 1,808.02% | 3,865.02% | 5,173.36% | 4,622.86% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |